BiotechTube

Upadacitinib + Corticosteroid (CS)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Giant Cell Arteritis (GCA)

Conditions

Giant Cell Arteritis (GCA)

Trial Timeline

Jan 24, 2019 → Mar 11, 2025

NCT ID
NCT03725202

About Upadacitinib + Corticosteroid (CS)

Upadacitinib + Corticosteroid (CS) is a phase 3 stage product being developed by AbbVie for Giant Cell Arteritis (GCA). The current trial status is completed. This product is registered under clinical trial identifier NCT03725202. Target conditions include Giant Cell Arteritis (GCA).

What happened to similar drugs?

5 of 13 similar drugs in Giant Cell Arteritis (GCA) were approved

Approved (5) Terminated (3) Active (6)
✅PexidartinibDaiichi SankyoApproved
✅Tocilizumab + PrednisoneRocheApproved
✅ValganciclovirRocheApproved
✅DenosumabAmgenApproved
✅XGEVA®AmgenApproved
🔄PexidartinibDaiichi SankyoPhase 3
🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03725202Phase 3Completed

Competing Products

20 competing products in Giant Cell Arteritis (GCA)

See all competitors
ProductCompanyStageHype Score
prednisoneKiniksa PharmaceuticalsPhase 2
29
PexidartinibDaiichi SankyoPhase 2
39
PexidartinibDaiichi SankyoPhase 3
44
PexidartinibDaiichi SankyoApproved
43
BaricitinibEli LillyPhase 2
35
dovitinibNovartisPhase 2
35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3
40
Secukinumab 300 mg, s.c. + Prednisolone + PlaceboNovartisPhase 2
35
SecukinumabNovartisPhase 1
29
Secukinumab 300 mg + Secukinumab 150 mgNovartisPhase 3
40
Tocilizumab + PlaceboRochePhase 3
44
Tocilizumab + PrednisoneRocheApproved
43
TocilizumabRochePhase 3
40
TocilizumabRochePhase 1
29
ValganciclovirRocheApproved
35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + MethotrexateRochePhase 3
40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)RochePhase 2
35
tocilizumab and IV steroids combinationRochePhase 2
31
DenosumabAmgenApproved
43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]AmgenPhase 2
27